We are delighted to welcome Piramal Imaging as a new corporate subscriber to the BIR. Piramal Imaging specialises in the pharmaceuticals involved in PET imaging of the brain to estimate beta-amyloid (AB) neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease and other causes of cognitive decline.
Dr David Wilson, President of the BIR said, “We are delighted to welcome Piramal Imaging to the BIR and hope that by joining the multi-disciplinary membership of our community, Piramal can engage with clinicians and organisations to make significant advances in the diagnostic imaging of Alzheimer’s disease. We feel great synergy with the core values of the Piramal Group—Knowledge, Action, Care—which are very much the ethos of our multi-disciplinary membership”.
Andrew Stephens, Chief Medical Officer of Piramal Imaging said, “As the science of diagnostic imaging of dementia becomes more developed, we are looking forward to working with the BIR to inform and educate the nuclear medicine community in the UK about AB PET imaging and clinical, technical, regulatory aspects of Neuraceq™”.
Image: Left to right: Angela Brewin, Market Access and HEOR Director, NW Europe (Piramal), Professor Andrew Jones, Past President BIR, Nico Beukman, Head of Commercial Operations NW Europe (Piramal), Amanda Walsh, Clinical Specialist (Piramal).
Corporate subscribers are encouraged to join the BIR special interest groups, to collaborate in developing educational events and to get involved with publishing activities.